{"brief_title": "Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome", "brief_summary": "To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .", "condition": ["Myelodysplastic Syndrome"], "intervention_type": ["Drug"], "intervention_name": ["CC-5013"], "criteria": "- Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration. - Baseline mean hemoglobin < 10.0 g/dL (untransfused) and/or be transfusion dependent defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline. - More than 30 days must have elapsed since any previous treatment for MDS, other than transfusion. - Women must not be pregnant or lactating - No use of another experimental study drug within 30 dy\\ays of baseline - Understand and sign written informed consent - Able to adhere to study visit schedule, understand and comply with other protocol requirements.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "CC-5013", "mesh_term": ["Syndrome", "Myelodysplastic Syndromes", "Preleukemia", "Lenalidomide", "Thalidomide"], "id": "NCT00044382"}